New scan technique may reveal early if kidney cancer drugs are effective
NCT ID NCT01224288
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a special type of CT scan (DCE-CT) can help doctors see if targeted therapy drugs for advanced kidney cancer are working. About 120 adults with metastatic renal cell carcinoma will get these scans before and shortly after starting treatment. The goal is to measure changes in tumor blood flow, which may indicate how well the drug is fighting the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who needs extra therapy after kidney cancer surgery?
- Can a Two-Drug combo outsmart advanced cancers?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a new nucleotide analogue boost cancer treatment?
- Can a blast of radiation make immunotherapy work better against kidney cancer?
- Can reprogrammed immune cells take on hard-to-treat kidney cancer?